Management and Board

Mr. Marcelo Hahn is the founder, member of the Board and CEO of Blau Farmacêutica, which was founded in 1987, after deciding to enter the Brazilian pharmaceutical segment.

Marcelo led the consolidation and expansion of the Company and is responsible for defining the general direction, the new business strategy and the execution of the company’s business plan.

Mr. Roberto is the Company’s M&A Officer, responsible for overseeing Blau’s M&A strategy.

Before joining Blau, Roberto served in executive positions in companies of the most varied branches, such as at GE Capital, Unibanco AIG Warranty, MHAG Mineração e Serviços, Barrera Pharma Representações Ltda and even held the position of CEO at São Miguel Holding e Investments.

Roberto has a degree in Mechanical Engineering from Escola Politécnica – USP and an MBA in Marketing from FIA / FEA.

Mr. Douglas is currently the Company’s Chief Financial and Investor Relations Officer, and between 2018 and 2021, he worked at Blau Farmacêutica in this same position.

Mr. Douglas holds an Accounting degree from Faculdade de Ciências Econômicas e Administrativos de Osasco – FEAO, specialized in finance and controllership from Faculdade Armando Álvares Penteado (FAAP) and holds an MBA in finance from IBMEC, having worked as a manager of different processes related to the financial, of controllership, costs, human resources, information technology and compliance in several companies in the health sector, such as Drogasil S.A., SIKA S.A., Wyeth Indústria Farmacêutica Ltda., Pfizer and Laboratório Teuto S.A., in various positions, until assuming the position of Administrative Financial Director.

Ms. Eliza Yukie Saito has been Blau’s quality director since November 2011, responsible for quality management and maintenance, in line with national and international standards for Good Manufacturing Practices and Quality Control.

She previously served in quality management positions for several pharmaceutical companies, such as Bunker Indústria Farmacêutica, Instituto Terapêutico Delta, Brasmédica and Laboratórios Biosintética Ltda. She joined Blau in 2001 as the Quality Assurance and Control Manager, and in November 2011 she became the Quality Director and since October 2016 she has also served as the Company’s Technical Responsible before the health surveillance agencies.

Eliza graduated in Pharmacy Biochemistry from Faculdade Oswaldo Cruz with a specialization in industry, has a postgraduate degree in Biotechnology from Universidade Mogi das Cruzes and Black Belt Certification.

Mr. Roberto Altieri is the legal director, responsible for supervising legal, litigation and administrative matters in regulatory, intellectual property, consumer, bidding and administrative, competitive, commercial and civil contracts in general.

Before joining the Company as Diretor, he worked as an independent lawyer, serving in addition to the company itself, several companies in the civil construction, agro and pharmaceutical sectors such as MPD – Engenharia, Agropec S.A., Laboratório Ativus, Arese Pharma, among others.

Altieri holds a law degree from the Largo de São Francisco Law School – University of São Paulo, with a specialization in Public and Private Law.

Rodolfo Alfredo Gerardo Hahn. Mr. Hahn holds a bachelor’s degree in economic sciences from the Faculdade de Ciências Econômicas in Buenos Aires, Argentina.

In 1966, he founded Laboratório Terápica Paulista Ltda., subsequently renamed Ariston Indústrias Químicas e Farmacêuticas Ltda., where he served as chief executive officer until 2007.

Mr. Hahn has been a member of our board of directors since 2011 and currently serves as Chairman.

Mr. Marcelo Hahn is the founder, member of the Board and CEO of Blau Farmacêutica, which was founded in 1987, after deciding to enter the Brazilian pharmaceutical segment.

Marcelo led the consolidation and expansion of the Company and is responsible for defining the general direction, the new business strategy and the execution of the company’s business plan.

Antonio Carlos Buzaid. Mr. Buzaid holds a medical degree from USP, where he received the Rockfeller Foundation award for the best student in the core subjects. He completed a hematology and oncology fellowship at the University of Arizona, where he received the Eleanor B Connel award for the best fellow.

Soon thereafter, he became an assistant professor at Yale University and served as medical director of the melanoma center and co-director of the lung cancer center at Yale University for four years.

He then became an associate professor at the MD Anderson Cancer Center Hospital and served as medical director of the multidisciplinary center for melanoma and skin cancer for five years. At the MD Anderson Cancer Center, Mr. Buzaid received the teacher of the year award. In 1998, he founded the oncology center at the Hospital Sírio-Libanês in the city of São Paulo with Dr. Raul Cutait and Frederico Costa. From 1998 to 2010, he served as director of the oncology center at the Hospital Sírio-Libanês.

In 2011, he became general director of the Antonio Ermírio de Moraes oncology center at the Hospital Beneficência Portuguesa in the city of São Paulo. In November 2015, he became a management committee member at the Dayan-Daycoval oncology center at the Hospital Israelita Albert Einstein.

José Antonio Miguel Neto. Mr. Miguel Neto holds a law degree from USP (1985). From 1989 and 1990, he worked as a lawyer at Stroeter, Trench e Veirano Advogados and from 1985 to 1989, he worked as a lawyer at Johnson and Johnson S/A. Since 1990, Mr. Miguel Neto has been a partner at Miguel Neto Advogados.

From 2004 to 2007, Mr. Miguel Neto was a tax and fees court judge for the Treasury Office of the State of São Paulo.

From 2010 to 2012, Mr. Miguel Neto served as president of Interlegal – Global Network for International Law Firms, headquartered in London. He also served as a member of the boards of directors of Companhia de Concessões Rodoviárias – CCR, Salomão e Zoppi Laboratórios de Diagnósticos S/A, Banco Fibra S.A., Chímica Baruel S/A and FLC – Lâmpadas, among others.

Mr. Roberto is the Company’s COO and M&A director, responsible for overseeing Blau’s M&A operation and strategy.

Before joining Blau, Roberto served in executive positions in companies of the most varied branches, such as at GE Capital, Unibanco AIG Warranty, MHAG Mineração e Serviços, Barrera Pharma Representações Ltda and even held the position of CEO at São Miguel Holding e Investments.

Roberto has a degree in Mechanical Engineering from Escola Politécnica – USP and an MBA in Marketing from FIA / FEA.

Ms. Andréa holds a business administration degree from Faculdade Nuno Lisboa, having also completed MBAs in human resources and administration, certificated by IBGC, FDC, ESPM, UGF, ICI USA Zurich Blue Academy and USA ABN Academy. She currently serves as a member of the IBGC People Commission, and member of the Board of Directors of Business Professional Women SP, with an executive position at FriendsBee, having already been in charge of Human Resources at Scania Brasil, Zurich Seguros, as well as an executive position at Banco Santander, Banco Real and Star One, whose responsibilities included the following roles in Environmental, Social and Governance topics: Safety, Health & Environment at Scania Commercial Operations Brazil, Ethics & Compliance for employees at Zurich Seguros and Social Responsibility Corporate, at Star One. In addition, integrates the groups People & ESG and People & Future Council, both of the IBGC.

Ms. Simone Agra has a degree in business administration from Universidade Presbiteriana Mackenzie, having also completed MBAs in Management, Marketing and Corporate Governance, certificated as a Board Member by the IBGC. Currently, she participates as an effective member of the Audit and Risk Committee and member of the Strategy Committee of Hospital Alemão Oswaldo Cruz and Independent Advisor of B2B Synthesis, having already served in the Board of Directors of ABIMED (Brazilian Association of High Technology Industry for Health Products), also served in the management committee of the Edwards Foundation and as an officer on Edwards Lifesciences, Allergan Pharmaceuticals and BD – Becton Dickinson.